CORE--CLINICAL

核心--临床

基本信息

  • 批准号:
    6484658
  • 负责人:
  • 金额:
    $ 20.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-08-15 至 2002-05-31
  • 项目状态:
    已结题

项目摘要

The Clinical Core is vital to the plans and success of the ADRC. It provides the primary interface between persons with dementia and the investigative community. The Core recruits and evaluates subjects with Alzheimer's Disease and related dementia (ADRD) syndromes, along with carefully matched healthy adults. The recruitment activities of the Clinical Core are closely coordinated with the efforts of the Minority Recruitment Satellite, the are giving Core, and the Education Core to enhance community awareness and enroll a demographically representative pool of volunteers. Core participants with dementia are evaluated annually to obtain standardized information on health history, functional status, and physical, cognitive and general neurologic examination findings, with the intent of fulfilling diagnostic criteria for Alzheimer's Disease or other recognized dementia syndromes. Participants also receive standardized evaluations of neuropsychological function, activities of daily living, behavioral symptoms, affect, and motivational statues to develop a longitudinal database on the clinical expression of ADRD. Blood samples are collected to allow current and future studies of the biology of ADRD in well-characterized subjects. When participants are no longer able to attend in person, and families are encouraged to continue longitudinal assessment of functional and behavior by telephone. The results of clinical evaluation are reviewed at a weekly Diagnostic Consensus Conference for research diagnosis and dementia severity assignments. Following Consensus diagnosis, the clinical data are released to the Data Management and Analysis Core for computerization and provision to investigators. A primary mission of the clinical Core is refer well-characterized clinical and control volunteers to investigators studying ADRD in greater Cleveland and collaborate in nationwide efforts to understand these devastating diseases. The Core carefully tracks subject participation in these studies in order to minimize attrition from undue burden. The Core maximizes subject retention by maintaining regular contact with registered volunteer families and providing services intended to maintain close, supportive, and long term working relationships with volunteer families. Finally, the Core facilitates brain donation by coordinating the autopsies performed by the Neuropathology Core.
临床核心对于ADRC的计划和成功至关重要。它提供了患有痴呆症和调查社区的人之间的主要接口。核心招募和评估患有阿尔茨海默氏病和相关痴呆症(ADRD)综合征的受试者,以及精心匹配的健康成年人。临床核心的招聘活动与少数族裔招募卫星的努力,核心和教育核心的努力紧密协调,以提高社区意识并招募人口统计学代表的志愿者库。每年评估患有痴呆症的核心参与者,以获取有关健康病史,功能状况以及身体,认知和一般神经系统检查结果的标准化信息,目的是满足阿尔茨海默氏病或​​其他公认的痴呆症综合症的诊断标准。参与者还获得了对神经心理学功能,日常生活的活动,行为症状,情感和动机雕像的标准评估,以开发有关ADRD临床表达的纵向数据库。收集血液样本,以允许在特征良好的受试者中对ADRD生物学的当前和将来的研究。当参与者不再能够亲自参加时,鼓励家庭继续通过电话进行纵向评估功能和行为。临床评估的结果将在每周一次的诊断共识会议上进行研究诊断和痴呆严重程度分配。在共识诊断后,将临床数据发布给数据管理和分析核心,用于计算机化和向研究人员提供。临床核心的主要任务是将良好的临床和控制志愿者转介给研究大克利夫兰ADRD的调查人员,并在全国范围内合作了解这些毁灭性疾病。核心仔细跟踪受试者参与这些研究,以最大程度地减少不适当负担的损耗。核心通过与注册志愿者家庭进行定期联系,并提供旨在维持与志愿者家庭的紧密,支持和长期工作关系的服务,从而最大程度地保持主题保留。最后,核心通过协调神经病理学核心进行的尸检来促进大脑捐赠。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID S GELDMACHER其他文献

DAVID S GELDMACHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID S GELDMACHER', 18)}}的其他基金

Clinical Core
临床核心
  • 批准号:
    10247594
  • 财政年份:
    2020
  • 资助金额:
    $ 20.26万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10035018
  • 财政年份:
    2020
  • 资助金额:
    $ 20.26万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10458123
  • 财政年份:
    2020
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6611072
  • 财政年份:
    2002
  • 资助金额:
    $ 20.26万
  • 项目类别:
Pioglitazone in Alzheimer's Disease Progression
吡格列酮在阿尔茨海默病进展中的作用
  • 批准号:
    6370732
  • 财政年份:
    2001
  • 资助金额:
    $ 20.26万
  • 项目类别:
Pioglitazone in Alzheimer's Disease Progression
吡格列酮在阿尔茨海默病进展中的作用
  • 批准号:
    6659849
  • 财政年份:
    2001
  • 资助金额:
    $ 20.26万
  • 项目类别:
Pioglitazone in Alzheimer's Disease Progression
吡格列酮在阿尔茨海默病进展中的作用
  • 批准号:
    6532554
  • 财政年份:
    2001
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6323232
  • 财政年份:
    2000
  • 资助金额:
    $ 20.26万
  • 项目类别:

相似海外基金

CORE--CLINICAL
核心--临床
  • 批准号:
    6611072
  • 财政年份:
    2002
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6327570
  • 财政年份:
    2000
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6314326
  • 财政年份:
    2000
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6334863
  • 财政年份:
    2000
  • 资助金额:
    $ 20.26万
  • 项目类别:
CORE--CLINICAL
核心--临床
  • 批准号:
    6323232
  • 财政年份:
    2000
  • 资助金额:
    $ 20.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了